- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04773054
Identification of Infections in Hip Arthroplasty Loosening.
Application of Advanced High-sensitivity Technologies for Identifying Infections in Patients With Aseptic Loosening of Hip Arthroplasty.
Recent data showed that the rate of periprosthetic infections in patients undergoing a hip arthroplasty revision for aseptic loosening is higher than what can be ascertained with conventional methods.
The study aims to assess the adequacy of next-generation sequencing of 16s ribosomal ribonucleic acid (rRNA) gene amplicons for identifying occult infections and improving the diagnostic workup. Moreover, additional testing has been planned in order to increase knowledge on the etiopathogenesis of infection.
Study Overview
Status
Conditions
Detailed Description
Periprosthetic infection following hip arthroplasty is one of the main causes of implant failure that leads to multiple surgical interventions, prolonged hospitalization, and higher complication rate and mortality.
Recent data prove that the rate of periprosthetic infections is higher than what can be ascertained with conventional techniques and highlight as analytical methods that allow an early and accurate diagnosis may help clinicians identify effective treatment and mitigate the devastating consequences.
New technologies based on culture-independent assays, i.e., the next-generation sequencing (NGS) of 16s rRNA gene amplicons, have entered medical microbiology as an alternative to traditional bacterial identification methods. NGS has been proven to detect microorganisms in culture-negative periprosthetic joint infection and seems to be a valid adjunct in identifying causative pathogens in samples from patients undergoing a hip arthroplasty revision for aseptic loosening.
The microbiota profiling using NGS may also help identify patients prone to develop infections. In predisposing clinical conditions, i.e., obesity and diabetes, the metabolic and nutritional alterations modify the composition and the immunomodulatory properties of intestinal microbiota. Saprophytic, non-pathogenic microorganisms usually found in the intestine and oral cavity can be transferred to other areas becoming a potential source of periprosthetic infection.
Additionally, microorganisms may live in the periprosthetic microenvironment without giving signs of overt infection. However, bacterial products, i.e., "microbe-associated molecular patterns" (MAMPs) or "pathogen-associated molecular patterns "(PAMPs), adhere to the implant surface or the wear particles and may elicit a local inflammatory response characterized by the presence of cells capable of producing cytokines that promote osteoclastogenesis, periprosthetic resorption and consequent loosening of the implant.
In summary, the current knowledge suggests that the hip arthroplasty loosening, classified as aseptic according to the preoperative clinical and laboratory investigations, could be directly or indirectly associated with infectious pathogenesis even if the microbial cultures on periprosthetic tissues are negative.
The investigators designed a small-scale study to assess the adequacy of NGS for identifying occult infections and improving the diagnostic workup in patients undergoing a hip arthroplasty revision for aseptic loosening. Moreover, additional testing has been planned to enhance knowledge on the role of unusual or difficult-to-cultivate microorganisms in the etiopathogenesis of implant failure.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bologna, Italy, 40136
- Istituto Ortopedico Rizzoli
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Hip arthroplasty revision for aseptic loosening, diagnosis determined as probable according to the following criteria:
- pain and/or functional impairment;
- radiographic signs of osteolysis following wear of the implant components, or cortical reaction, or periprosthetic bone resorption;
- negative evaluation by the infectious disease specialist.
Exclusion Criteria:
- presence of a sinus tract communicating with the arthroplasty;
- bacteria isolation from aspirates or blood cultures performed preoperatively;
- serum C-reactive protein higher than 10 mg/L;
- recurrent implant dislocations;
- prosthetic fracture;
- medical history for septic arthritis, osteomyelitis;
- infections in anatomic areas other than hip;
- antibiotic therapy in the 15 days prior to surgery (with the exception of preoperative antibiotic prophylaxis);
- chronic treatment with immunosuppressive drugs;
- medical contraindications for executing sample collection.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Identification of microorganisms by microbiological cultures (number of patients with positive microbiological culture).
Time Frame: Within two week of admission
|
Tissue samples will be sent for microbiological cultures and treated for the isolation of aerobic and anaerobic pathogens.
The existence of two positive cultures will be considered to be diagnostic for periprosthetic infection; a single positive culture may occur from a contaminating organism and will be considered in conjunction with other markers of infection, including histological features.
|
Within two week of admission
|
|
Number of patients with histological features of periprosthetic infection
Time Frame: Within two week of admission
|
The presence of a periprosthetic infection will be established according to the number of polymorphonuclear cells (PMN) counted in ten high-power fields (HPF) (400 × magnification, field diameter 0.54 mm)- Uninfected: 0-5 PMNs in 10 HPFs; borderline, but probably not infected: 6-10 PMNs for 10 HPF; borderline, but probably infected: >10 PMNs for 10 HPFs (but not > 5 PMNs in a single HPF); infected > 5 for HPF.
|
Within two week of admission
|
|
Identification of microorganisms by next-generation sequencing (NGS) (number of patients with positive NGS).
Time Frame: Through study completion, an average of 6 months.
|
The NGS will be employed to characterize the overall microbiome profile in tissue samples, and bioinformatics used to determine the taxonomic and phylogenetic affiliation, alpha-diversity (ecological diversity of a single sample according to the number of different taxa and their relative abundances), and beta-diversity (differences in microbial community composition between samples).
|
Through study completion, an average of 6 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Characterization of taxonomic and phylogenetic affiliation of gut microbiota
Time Frame: Through study completion, an average of 6 months.
|
The NGS technology will be employed to characterize the overall microbiome profile in stool samples, and bioinformatics used to determine the taxonomic and phylogenetic affiliation.
|
Through study completion, an average of 6 months.
|
|
Characterization of alpha-diversity and beta-diversity of gut microbiota
Time Frame: Through study completion, an average of 6 months.
|
The NGS technology will be employed to characterize the overall microbiome profile in stool samples, and bioinformatics used to determine alpha-diversity (ecological diversity of a single sample according to the number of different taxa and their relative abundances) and beta-diversity (differences in microbial community composition between samples).
|
Through study completion, an average of 6 months.
|
|
Characterization of taxonomic and phylogenetic affiliation of oral microbiota
Time Frame: Through study completion, an average of 6 months.
|
The NGS technology will be employed to characterize the overall microbiome profile in oral swab, and bioinformatics used to determine the taxonomic and phylogenetic affiliation.
|
Through study completion, an average of 6 months.
|
|
Characterization of alpha-diversity and beta-diversity of oral microbiota
Time Frame: Through study completion, an average of 6 months.
|
The NGS technology will be employed to characterize the overall microbiome profile in oral swab, and bioinformatics used to determine alpha-diversity (ecological diversity of a single sample according to the number of different taxa and their relative abundances) and beta-diversity (differences in microbial community composition between samples
|
Through study completion, an average of 6 months.
|
|
Number of patients with inflammatory cellular reactivity related to bacterial products.
Time Frame: Through study completion, an average of 6 months.
|
The inflammatory cellular reactivity proved by the presence of activated macrophages and Toll-like-receptor positive cells.
|
Through study completion, an average of 6 months.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nicola Baldini, University of Bologna, Istituto Ortopedico Rizzoli
Publications and helpful links
General Publications
- Goswami K, Parvizi J. Culture-negative periprosthetic joint infection: is there a diagnostic role for next-generation sequencing? Expert Rev Mol Diagn. 2020 Mar;20(3):269-272. doi: 10.1080/14737159.2020.1707080. Epub 2019 Dec 24. No abstract available.
- Tarabichi M, Shohat N, Goswami K, Alvand A, Silibovsky R, Belden K, Parvizi J. Diagnosis of Periprosthetic Joint Infection: The Potential of Next-Generation Sequencing. J Bone Joint Surg Am. 2018 Jan 17;100(2):147-154. doi: 10.2106/JBJS.17.00434.
- Pajarinen J, Jamsen E, Konttinen YT, Goodman SB. Innate immune reactions in septic and aseptic osteolysis around hip implants. J Long Term Eff Med Implants. 2014;24(4):283-96. doi: 10.1615/jlongtermeffmedimplants.2014010564.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAS-ASEPTIC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Loosening, Prosthesis
-
Sahlgrenska University Hospital, SwedenCompletedProsthesis LooseningSweden
-
University Hospital, LimogesTerminatedProsthesis LooseningFrance
-
Reinier Haga Orthopedisch CentrumEnrolling by invitation
-
Region SkaneCompletedAseptic Loosening of the Hip ProsthesisSweden
-
Istituto Ortopedico RizzoliSmith & Nephew, Inc.Active, not recruitingLoosening, ProsthesisItaly
-
Georgios Tsikandylakis, MD PhDSectra AB, SwedenNot yet recruitingHip Arthropathy | Loosening, ProsthesisNorway, Sweden, Denmark
-
Medtronic Surgical TechnologiesCompletedInfection of Total Knee Joint Prosthesis | Aseptic Loosening of Prosthetic JointGermany
-
Turku University HospitalCompletedInfection of Total Hip Joint Prosthesis | Adverse Reactions to Metal Debris | Mechanical Loosening of Prosthetic JointFinland
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Sint MaartenskliniekRecruitingKnee Arthroplasty, Total | Aseptic Loosening | Aseptic Loosening of Prosthetic Joint | Aseptic Loosening of Orthopaedic Hardware | Total Knee Arthroplasty (replacement)Netherlands
-
Centre Hospitalier Universitaire, AmiensCompletedArthroplasty Complications | Aseptic Loosening
Clinical Trials on Microbiological analysis of periprosthetic tissue
-
Rennes University HospitalCompleted
-
University of BolognaCompletedType 2 Diabetes Mellitus | Chronic PeriodontitisItaly
-
Military Institute of Medicine, PolandCompletedIntensive Care Unit | Bloodstream Infection | Antibiotic Resistant StrainPoland
-
Charite University, Berlin, GermanyPro-Implant Foundation; Ceram Tec GmbHUnknownTotal Hip Replacement | Biofilm | SonicationGermany
-
Centre Hospitalier Universitaire de BesanconInstitut de Science des Matériaux de Mulhouse IS2M; NOVOTEC labs (lyon)RecruitingBreast Implant; Complications | Breast Expansion ProsthesisFrance
-
Centre Hospitalier Universitaire VaudoisUniversity Children's Hospital BaselUnknownInfectionSwitzerland
-
University Hospital OstravaThomayer University Hospital; University Hospital Bulovka; Institute of Microbiology...Recruiting
-
Kepler University HospitalCompleted
-
University of LisbonNot yet recruitingPeriodontitis | Alzheimer Disease
-
Northside Hospital, Inc.Blood and Marrow Transplant Group of GeorgiaCompletedPulmonary Infiltrate NewUnited States